These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 12039922)

  • 1. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies.
    Nadella P; Shapiro C; Otterson GA; Hauger M; Erdal S; Kraut E; Clinton S; Shah M; Stanek M; Monk P; Villalona-Calero MA
    J Clin Oncol; 2002 Jun; 20(11):2616-23. PubMed ID: 12039922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.
    Han JY; Lee DH; Kim HY; Hong EK; Yoon SM; Chun JH; Lee HG; Lee SY; Shin EH; Lee JS
    Cancer; 2003 Nov; 98(9):1918-24. PubMed ID: 14584075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
    Pronk LC; Vasey P; Sparreboom A; Reigner B; Planting AS; Gordon RJ; Osterwalder B; Verweij J; Twelves C
    Br J Cancer; 2000 Jul; 83(1):22-9. PubMed ID: 10883663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
    Fujimoto-Ouchi K; Tanaka Y; Tominaga T
    Clin Cancer Res; 2001 Apr; 7(4):1079-86. PubMed ID: 11309360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
    Puglisi F; Cardellino GG; Crivellari D; Di Loreto C; Magri MD; Minisini AM; Mansutti M; Andreetta C; Russo S; Lombardi D; Perin T; Damante G; Veronesi A
    Ann Oncol; 2008 Sep; 19(9):1541-6. PubMed ID: 18441329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.
    Ramanathan RK; Ramalingam S; Egorin MJ; Belani CP; Potter DM; Fakih M; Jung LL; Strychor S; Jacobs SA; Friedland DM; Shin DM; Chatta GS; Tutchko S; Zamboni WC
    Cancer Chemother Pharmacol; 2005 Apr; 55(4):354-360. PubMed ID: 15723261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
    Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW
    Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
    Villalona-Calero MA; Weiss GR; Burris HA; Kraynak M; Rodrigues G; Drengler RL; Eckhardt SG; Reigner B; Moczygemba J; Burger HU; Griffin T; Von Hoff DD; Rowinsky EK
    J Clin Oncol; 1999 Jun; 17(6):1915-25. PubMed ID: 10561233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taxanes and capecitabine in combination: rationale and clinical results.
    Maher JF; Villalona-Calero MA
    Clin Breast Cancer; 2002 Jan; 2(4):287-93. PubMed ID: 11899360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients.
    Villalona-Calero MA; Blum JL; Jones SE; Diab S; Elledge R; Khoury P; Von Hoff D; Kraynak M; Moczygemba J; Kromelis P; Griffin T; Rowinsky EK
    Ann Oncol; 2001 May; 12(5):605-14. PubMed ID: 11432617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
    Ernst T; Merx K; Gnad-Vogt U; Lukan N; Kripp M; Schultheis B; Hochhaus A; Hofheinz RD
    Br J Cancer; 2007 Dec; 97(11):1475-9. PubMed ID: 18000507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer.
    Kindwall-Keller T; Otterson GA; Young D; Neki A; Criswell T; Nuovo G; Soong R; Diasio R; Villalona-Calero MA
    Clin Cancer Res; 2005 Mar; 11(5):1870-6. PubMed ID: 15756012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.
    Saif MW; Lansigan F; Ruta S; Lamb L; Mezes M; Elligers K; Grant N; Jiang ZL; Liu SH; Cheng YC
    Phytomedicine; 2010 Mar; 17(3-4):161-9. PubMed ID: 20092990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
    O'Shaughnessy J; Miles D; Vukelja S; Moiseyenko V; Ayoub JP; Cervantes G; Fumoleau P; Jones S; Lui WY; Mauriac L; Twelves C; Van Hazel G; Verma S; Leonard R
    J Clin Oncol; 2002 Jun; 20(12):2812-23. PubMed ID: 12065558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer.
    Mrozek E; Ramaswamy B; Young D; Rhoades CA; Kendra K; Allen J; Moore T; Hauger M; Watson H; Merriman N; Nadella P; Villalona-Calero M; Shapiro CL
    Clin Breast Cancer; 2006 Jun; 7(2):141-5. PubMed ID: 16800973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.
    Wagstaff AJ; Ibbotson T; Goa KL
    Drugs; 2003; 63(2):217-36. PubMed ID: 12515569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-finding study of capecitabine in combination with weekly paclitaxel for patients with anthracycline-pretreated metastatic breast cancer.
    Susnjar S; Bosnjak S; Radulovic S; Stevanovic J; Gajic-Dobrosavljevic M; Kreacic M
    J BUON; 2007; 12(2):189-96. PubMed ID: 17600871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
    Kruth J; Nissen J; Ernst T; Kripp M; Lukan N; Merx K; Hofmann WK; Hochhaus A; Hofheinz RD
    J Cancer Res Clin Oncol; 2010 Dec; 136(12):1845-51. PubMed ID: 20224968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
    Campone M; Isambert N; Bourbouloux E; Roché H; Bonneterre J; Milano G; Fumoleau P
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.